Amylyx Pharmaceuticals, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for AMLX, updated each market day.
AMLX AI Sentiment
AI predicts Amylyx Pharmaceuticals, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Amylyx Pharmaceuticals, Inc. Common Stock
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Sector
Exchange
Market Cap
$1,914,499,870
Cap Tier
Employees
136
Headquarters
CAMBRIDGE, MA
Listed Since
Jan. 7, 2022
Website
AMLX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
AMLX Volatility
Amylyx Pharmaceuticals, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
